Trials / Completed
CompletedNCT04782271
Safety, Tolerability and Pharmacokinetic Profile of SYL1801 Eye Drops
Safety, Tolerability and Pharmacokinetic Profile of Different Doses of SYL1801 Ophthalmic Solution in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Sylentis, S.A. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
Study of the safety, tolerability and pharmacokinetic profile of different doses of SYL1801 eye drops in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SYL18001 sodium Low dose q.d | 1 drop in the randomized eye once daily |
| DRUG | SYL18001 sodium Middle dose q.d | 1 drop in the randomized eye once daily |
| DRUG | SYL18001 sodium High dose q.d | 1 drop in the randomized eye once daily |
| DRUG | SYL18001 sodium High dose b.i.d | 1 drop in the randomized eye twice daily |
Timeline
- Start date
- 2021-03-17
- Primary completion
- 2021-12-21
- Completion
- 2021-12-21
- First posted
- 2021-03-04
- Last updated
- 2022-03-31
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT04782271. Inclusion in this directory is not an endorsement.